<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04186442</url>
  </required_header>
  <id_info>
    <org_study_id>HG-BOTOAB-PI-01</org_study_id>
    <nct_id>NCT04186442</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase I Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hugel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of Botulax® in treatment of Overactive Bladder
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase I Clinical Trial
      to Compare the Safety and Efficacy of Botulax® versus Botox® in Patient with Overactive
      Bladder
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event incidence rates</measure>
    <time_frame>12 weeks (during the clinical trial)</time_frame>
    <description>To assess severity and frequency of reported TEAE (treatment-emergent adverse event), ADR (adverse drug reaction), and SAE (serious adverse event) after investigational product injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary incontinence rate</measure>
    <time_frame>Baseline to Week 2, Week 6, Week 12</time_frame>
    <description>The change in the average number of Urinary incontinence per day at 2, 6 and 12 weeks from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voiding frequency rate</measure>
    <time_frame>Baseline to Week 2, Week 6, Week 12</time_frame>
    <description>The change in the average number of voiding frequency per day at 2, 6 and 12 weeks from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary urgency rate</measure>
    <time_frame>Baseline to Week 2, Week 6, Week 12</time_frame>
    <description>The change in the average number of urinary urgency (Urgency Rating Scale; URS≥2)per day at 2, 6 and 12 weeks from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin type A (Botulax®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum toxin type A (Botox®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A injection</intervention_name>
    <description>Experimental</description>
    <arm_group_label>Botulinum toxin type A (Botulax®)</arm_group_label>
    <other_name>Botulax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A Injection [Botox]</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Botulinum toxin type A (Botox®)</arm_group_label>
    <other_name>Botox®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female at the age of 19 or older

          2. Subjects who agree to participate in the clinical study and voluntarily sign the
             written informed consent form

          3. Subjects with idiopathic overactive bladder who meets the following conditions:

               1. Subjects with persistent overactive bladder symptoms for the last 12 weeks

               2. Subjects who are not properly controlled by the administration of anticholinergic
                  agents for 4 weeks or more or who are difficult to treat due to adverse reactions

               3. Subjects with urinary incontinence, urgency, and urinary frequency symptoms

          4. Subjects who are willing to perform clean intermittent catheterization (CIC), if
             needed

        Exclusion Criteria:

        Subjects who are eligible for any of the following conditions may not participate in this
        study:

          1. Subjects with the following comorbidities:

               1. Subjects with peripheral motor neuron disease (eg. amyotrophic lateral sclerosis,
                  motor neuropathy) or systemic neuromuscular junction disorders (eg. myasthenia
                  gravis, Lambert-Eaton syndrome)

               2. Overactive bladder patients due to neurological factors (eg stroke, spinal cord
                  disease, Parkinson's disease, etc.)

               3. Subjects with clinically significant stress incontinence

               4. Subjects with Urinary Tract Infections*

                  * Culture showing ≥10^5 colony-forming units (CFU)/mL and leukocytes ≥5 high
                  power field (HPF)

               5. Patients with acute urinary retention, or with a history or accompanying diseases
                  that can cause urinary retention (urolithiasis, acute cystitis, foreign body in
                  the bladder, bladder flow, etc.)

               6. Uncontrolled diabetes patients who meet one or more of the following criteria:

                    -  HbA1c ≥ 9% at screening

                    -  Patients with over 10 years of diabetes

                    -  Have diabetic chronic complications (eg diabetic neuropathy, diabetic
                       nephropathy, diabetic retinopathy, etc.)

                    -  Patients taking a drug that causes glycosuria (sodium-glucose co-transporter
                       2 inhibitor, SGLT2 inhibitor)

          2. Those who have had lower urinary tract surgery within 24 weeks before screening

          3. Those who received botulinum toxin due to urinary system disease within 24 weeks
             before screening

          4. Those who have been administered botulinum toxin type A within 12 weeks prior to
             screening or botulinum toxin type B within 16 weeks of treatment, or planned during
             the clinical trials

          5. Those who have received or plan to receive oral medications for overactive bladder
             including anticholinergic drugs within 1 week prior to randomization

          6. Those who received antiplatelet and anticoagulants within 1 week prior to
             randomization

          7. Subjects with a history of hypersensitivity reactions to any of the components of the
             investigational product

          8. Women of childbearing potential who are planning to become pregnant during the
             clinical trials or are not using an appropriate method of contraception

          9. Those who participated in another clinical trial within 12 weeks prior to screening
             and received investigational product/medical device/medical procedure

         10. Those who are sensitive to cephalosporin or penicillin antibiotics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jin-Hong Park</last_name>
    <phone>82-2-6966-1651</phone>
    <email>jhpark@hugel.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hugel</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06162</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

